{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-146874","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2025-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.287893+00:00","generated_at":"2026-05-18T19:31:41.623099+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"confidence":"high","headline":"Enliven Therapeutics stockholders elect three Class II directors, ratify Deloitte as auditor at 2025 annual meeting","bullets":["Elected Class II directors: Rahul D. Ballal (36,870,420 for), Jake Bauer (37,250,826 for), Andrew Phillips (31,957,928 for).","Ratified Deloitte & Touche LLP as independent auditor for FY2025 (45,392,647 for, 2,435 against, 35,215 abstain).","Broker non-votes of 8,099,804 existed for director elections; ratification had no broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-146874","json":"https://secwatch.observer/filing/0001193125-25-146874.json","markdown":"https://secwatch.observer/filing/0001193125-25-146874.md","text":"https://secwatch.observer/filing/0001193125-25-146874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312525146874/0001193125-25-146874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312525146874/d80015d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T19:31:41.623099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}